Three different methods for determination of CD34 ؉ cells in G-CSF-mobilized peripheral blood were compared. The methods were: the Milan/Mulhouse protocol, the ISHAGE guidelines for CD34
The ever more frequent use of peripheral blood stem cells (PBSC) to reconstitute hematopoiesis after myeloablative therapy [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] has prompted the need for a standardized method for estimation of CD34
+ cells in stem cell harvests. Flow cytometry represents a valuable tool to quantitate the progenitors in mobilized peripheral blood and to evaluate in real time the engraftment potential of the cytapheresis product. 11 In this regard, several assays for CD34 + cell enumeration have been proposed, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] but lack of homogeneous procedures has resulted in the generation of controversial data. Historically, the first attempt at enumerating CD34 + progenitors by flow cytometry was based on the evaluation of HPCA-2 FITC/PE positive cells with a low light scatter (SSC), after initial forward vs SSC live gating excluding debris, platelets, erythrocytes and cell aggregates. 12, 13 This very simple protocol was subsequently validated in three Nordic workshops involving 28 laboratories. 17 The more recently proposed ISHAGE protocol 16 is based upon the addition of a second antibody staining with CD45 FITC to exclude undesired populations and a sequential gating strategy to select CD34 + CD45 +dim cells which are supposed to be the genuine hematopoietic precursors. We developed in our laboratory a simplified method for CD34
+ cell enumeration 21 and compared it with the Milan/Mulhouse 14 and ISHAGE protocols. Our procedure is based upon a single staining with HPCA-2 PE and a multiparametric approach using the PAINT-A-GATE software analysis program (Becton Dickinson Immunocytometry System (BDIS), San Jose, CA, USA). Such a method has proven to be simple, feasible and achieved a significant correlation with clinical data. We have also assessed the usefulness of introducing a double staining with CD45, performing a triple immunofluorescence assay with CD34, CD45 and CD38. This approach has demonstrated the presence, among the CD34 + cell fraction, of a small subset which is CD38-positive and CD45-negative. Based on this, we also investigated the morphology of the subsets CD34 + CD45
+ and CD34 + CD45 − . This was possible by using a new technology known as laser scanning cytometry which provided evidence that the two subsets of progenitors have indeed common morphological characteristics.
Materials and methods

Patient population
The peripheral blood samples for this study were obtained under local institutional review board protocols and were collected from 70 patients affected by acute leukemia (31), non-Hodgkin's lymphoma (10), Hodgkin's lymphoma (5), multiple myeloma (19) and breast cancer (5) . PBSC collection was performed following chemotherapy and mobilization with subcutaneous granulocyte colony-stimulating factor (G-CSF) at 5-10 g/kg/day. The aphereses were initiated when the number of CD34 + cells was у20 × 10 6 /l or alternatively when the white blood cell (WBC) count exceeded 1 × 10 9 /l. On consecutive days, two to five cytaphereses were performed processing about 10-12 litres of blood using a continuous flow centrifuge (Fenwal CS-3000 Plus; Baxter, Fenwal, Round Lake, IL, USA). A minimum target of 2 × 10 6 /kg CD34 + cells was considered an acceptable harvest to ensure a safe transplant. On average, three aphereses per patient were performed and a total of 204 aphereses samples were analyzed. BuCy (busulfan 16 mg/kg, cyclophosphamide 60 mg/kg), melphalan (200 mg/m , cyclophosphamide 140 mg/kg) were the conditioning regimens used. All patients were given post-transplant G-CSF which was started on day 1 until absolute neutrophil count (ANC) recovery defined as an ANC у0.5 × 10 9 /l for 3 consecutive days. Likewise, platelet (PLT) recovery was defined as the number of days required to reach a number of PLT count у20 × 10 9 /l without transfusional support.
Monoclonal antibodies (MoAbs)
All monoclonal antibodies were derived from mouse hybridomas. Unconjugated and FITC/PE conjugated 8G12 (HPCA-2), CD38-PE (Leu-17), CD45-FITC/PerCP (HLe-1) monoclonal antibodies were purchased from BDIS.
Sample preparation
Cell samples were maintained on ice and stained within 4 h of collection; trypan-blue exclusion viability test was performed before the sample preparation. For each sample, three tubes were prepared and processed in parallel: (1) single staining with CD34 PE; (2) double staining with CD34 PE and CD45 FITC; and (3) triple staining with CD34 FITC, CD38 PE and CD45 PerCP. Matched isotype negative controls were also used to enumerate nonspecific events that exhibited the fluorescence and light scatter characteristics of genuine CD34 + cells. These events were subsequently subtracted from the number of CD34 + cells estimated in the stained sample. When necessary, the samples were diluted to adjust the leukocyte count at less than 20 × 10 9 /l and 100 l aliquots were placed into roundbottom tubes (No. 2054 Falcon; Becton Dickinson Labware, NJ, USA) and incubated with 10 l of monoclonal antibodies at 4°C for 30 min. Lysis of red blood cells was performed by adding ammonium chloride lysing reagent (Ortho, Raritan, NJ, USA); the cells were than pelletted twice at 400 g at 4°C for 5 min and finally resuspended in phosphate-buffered solution and run on to the cytometer soon after preparation. Competition experiments were also performed in order to verify whether dim CD34 + cells were genuine or not. Briefly, cells were pre-incubated with an excess of unconjugated HPCA-2 followed by staining with PE conjugated HPCA-2.
Sample acquisition and analysis
All samples were processed on a Facscan (BDIS) equipped with a 488 nm argon laser and connected to a MacIntosh PC Power hardware (Apple Computers Inc, Cupertino, CA, USA). An FSC vs SSC live-gate was set in acquisition to exclude debris, platelets and cellular aggregates. All parameters of interest were stored in listmode files. Forward and side light scatter were recorded using linear amplification and FL1, FL2 and FL3 using a logarithmic amplification. In order to comply with statistical requirements, 100 CD34 + events or alternatively 75 000 total events were acquired for each sample. For samples whose percentage of CD34 + cells was р0.1% the acquisition was repeated and terminated when virtually all the cells in the tube had passed through the cytometer. Analysis was performed according to the published Milan/Mulhouse 12, 17 or ISH-AGE 16 protocols and according to our own procedure using a PAINT-A-GATE software analysis program. This program provides multidimensional, multicolor analysis of FACS-acquired list-mode data files. It allows classification of events by painting them different colors and then quantification of these populations as a percentage of the total events. This is in order to visualize in different plots cell populations that are difficult to see in two dimensions. This software also allows improved separation between populations with the Transform SSC (tSSC) feature. This is a mathematical function which: (1) expands the lymphocyte region into more of the SSC data space; (2) separates the lymphocyte region from the monocytes in SSC; and (3) contracts the neutrophil region into a smaller data space (Figure 1a, b) . The gating strategy which we applied was as follows: (1) on SSC vs CD34 PE dot plot, a gate was set encompassing both dim and bright CD34
+ events with a low SSC (Figure 2a , red dots); (2) on FSC vs SSC dot plot, a gate was drawn including events with 
Calculation of CD34
+ cells
The total number of CD34 + cells was calculated multiplying the percentage of CD34
+ cells as estimated with each method, by the total number of nucleated cells in the apheresis sample, which was the product of the WBC count from the STKS automated hematological analyzer (Coulter, Hialeah, FL, USA) and the volume of the harvest. This number was divided by the actual weight of the patient to give the total number of CD34 + cells/kg.
Laser scanning examination
Recently, an innovative cytometric approach, referred to as laser scanning cytometry, has been developed by Kamentsky and Kamentsky. 26 Here we applied this method to investigate the morphology of CD34 + CD45 + and CD34 + CD45 − cells. CD34
+ circulating progenitors were purified from small aliquots of leukapheresis products using gradient isolation (Ficoll-Paque 1.077 g/ml) and a CD34 isolation kit (Milteny Gladbach, Germany) in accordance with the manufacturer's instructions. One hundred microliters of cell suspension containing up to 2.5 × 10 5 freshly purified (99% purity) CD34
+ cells were mixed with 10 l of FITC-conjugated anti-CD45 MoAbs, and incubated for 30 min at room temperature in the dark. Then, the cells were washed twice with PBS additioned with 1% bovine serum albumin and analyzed for CD45 expression by flow cytometry. The same cell suspension used for the flow analysis underwent examination by laser scanning cytometry (LSC; Compucyte, Cambridge, MA, USA). To this end cytospins were prepared by a Shandon cytocentrifuge (Shandon, Pittsburgh, PA, USA), air-dried in the dark overnight and mounted under coverslips in 50% PBS buffered glycerol with 1 g/ml 7-AAD. The latter served to restrict analysis to cells with intact nuclei, avoiding debris and disrupted cells, a potential source of artefacts in this kind of measurement. LSC is a microscope-based cytometer able to measure the fluorescence of individual cells attached to a microscope slide and produce data comparable to that obtainable by a flow cytometer. After data acquisition, slides were briefly dipped into PBS to remove coverslips, air-dried and stained with May-Grünwald-Giemsa. A morphological examination was then carried out on cells selected on the basis of CD45 staining by exploiting the relocating capability of LSC that memorizes the spatial X-Y coordinates of each cell on the slide. 27 
Colony forming unit granulocyte-macrophage (CFU-GM) assay
Semisolid culture assays were used to grow hematopoietic progenitor cells. PBSCs were cultured in a standard growth factor supplemented methylcellulose medium (MethoCult GF H4434) provided by Stem Cell Technologies (Vancouver, Canada) and containing recombinant human (rh) GM-CSF (10 ng/ml), rh-SCF (50 ng/ml), rh-IL3 (10 ng/ml), rh-erythropoietin (3 U/ml) and 25% fetal bovine serum. Briefly, colony assays were performed in a quadruplicate fashion using two concentrations (2 × 10 4 and 4 × 10 4 nucleated cells/dish). The cells were incubated for 14 days at 37°C in a humidified atmosphere containing 5% CO 2 air. After a 14-day incubation period, colonies consisting of 50 cells or more were counted as CFU-GM. The number of infused CFU-GM was quantitated by multiplying total infused cells by plating efficiency.
Statistical analysis
The degree of correlation between the percentage and absolute number of CD34 + cells from each method was calculated using the linear regression test. The relationship of CD34 + cells/kg and time to granulocyte and platelet recovery was analyzed using Spearman's correlation test. The Spearman's test was also used to determine the relationship of CFU-GM/kg and each method. Significance levels were set at P р 0.05. Finally, a Bland-Altman plot 28 was built in a logarithmic fashion to graphically visualize the 'agreement' between the three methods. The gating strategy of our protocol is shown. In the first step both dim and bright CD34 + cells are selected (a, red dots). In the second step a gate is drawn on FSC vs SSC plot including events with low/intermediate FSC and low SSC features (b, yellow dots). After the activation of the tSSC function, adequate corrections were made on FSC vs SSC dot plot excluding those events that did not exhibit the expected features and that were difficult to distinguish in the normal plot (c, black dots). /kg (range 0.008-599) for our protocol. Again, the regression analysis documented a good correlation between the methods (Table 1b) . Although the three protocols corre- 29 In this regard, we performed a series of epitope-blocking experiments to demonstrate that CD34 +dim cells are bona fide progenitors. 30 In fact, preincubation with pure 8G12 MoAb causes complete epitope blocking thus hampering the binding of the identical but PE conjugated MoAb. The inhibition of the specific sites results in a lack of staining of genuine CD34
Results
Overall
+ cells (both dim and bright), whereas unspecific neutrophil/monocyte binding still persists with a typical high tSSC. Contrary to ISHAGE guidelines, we do believe that CD34 + CD45 − events should be included in the final estimation since in the setting of triple immunofluorescence assays, combining CD34, CD38 and CD45, a small fraction of CD34 + CD38 + CD45 − cells with typically low tSSC properties was identified (median 0.07%, range 0.02-0.56 of the total nucleated cells, median 4%, range 1-20%, of CD34 + cells). In order to address this issue better we used an innovative technology known as LSC which allows assessment of the morphology relative to different subsets of cells contained in a mixed population without altering their natural features. This is possible because the cell selection is based on multiparametric gating with a relocation of the gated events on the original slide, and not on the physical separation of the events of interest. The comparison of CD34 + CD45 + and CD34 + CD45 − cells shows that these two populations share the same morphological characteristics (Figure 4a /kg (range 2-599) for our protocol. The median time required to reach an ANC у0.5 × 10 9 /l was 11 days (range 9-24) and that to reach a PLT у20 × 10 9 /l 20 days (range 10-70). The Spearman's rank test showed a significant negative correlation between the number of CD34 + cells/kg, as calculated with each protocol, and days to ANC/PLT engraftment (Table 2) . However, the best correlation between time to engraftment and number of CD34 + /kg was observed for our protocol (r = −0.40 and P = 0.015 for ANC recovery, r = −0.46 and P = 0.005 for PLT recovery) ( Table 2) .
The median number of CFU-GM reinfused was 12.57 × 10 4 /kg (range 1.43-465), and a significant correlation was observed between each method and the number of CFU-GM (r = 0.68 for the Milan/Mulhouse protocol, 0.66 for the ISHAGE one and 0.69 for our protocol; all were P Ͻ 0.01). Finally, in order to further explore whether the methods differ from each other, we used an alternative statistical approach aimed at assessing the degree of 'agreement'. 28 This is a graphical representation of the difference between the methods against their mean and the results are depicted in Figure 5 . In line with the results of regression analysis, the methods are indeed comparable since considerable discrepancies do not exist and the degree of agreement is acceptable (disagreement = 2.45% in ISHAGE vs Table 2 The number of reinfused progenitors as calculated according to the three protocols and results of engraftment analysis Days to reach an ANC у500 × 10 9 /l median 11 range 9-24
Days to reach a PLT count у20 × 10 9 /l median 20 range 10-70 our protocol, 4.9% in Milan/Mulhouse vs our protocol and 1.9% in ISHAGE vs Milan/Mulhouse).
Discussion
As myeloablative therapy followed by PBSC rescue is increasingly used as a new therapeutic option, flow cytometric determination of CD34 + cells has rapidly become the tool of choice for quantitating circulating hematopoietic progenitors, for establishing their minimum number to ensure the engraftment and the optimal timing of cytaphereses. Despite the rapidity and reliability of the cytometric assays, quality assessment programs have previously reported conspicuous interlaboratory variation with CVs as high as 284%, thus prompting the need for standardization of CD34 + cell enumeration technology. 31, 32 Accordingly, several workshops have demonstrated that the adoption of standard protocols improves the interlaboratory variation and increases the level of agreement. [31] [32] [33] [34] In order to contribute to this issue we have compared three different methods of CD34 + cell enumeration: the Milan/Mulhouse protocol, 12 the ISHAGE protocol 16 and our own protocol 21 with the aim of verifying the differences between them, especially in terms of clinical impact. Our very simple procedure is basically a Milan/Mulhouse protocol-derived methodology combined with a multiparametric approach based on the use of a the PAINT-A-GATE software analysis program. This program takes advantage of the possibility of painting various populations simultaneously, rendering them easily identifiable. This function appears especially useful to visualize minor subsets difficult to see in two dimensions. A further discrimination of different populations is possible with the tSSC function which distributes the events more evenly in the data space making the cells of interest easier to gate (Figure 1) . We started our analysis by evaluating to what extent the three methods differ from each other. Regression analysis, performed using the percentage and the absolute number of CD34 + cells/kg achieved by each method, indicates that they do indeed correlate (Table 1 ). In spite of the excellent correlation between the three methods, from a methodological point of view the criteria of evaluation proposed in our protocol are slightly different, due to the inclusion in the final calculation of both CD34 +dim (Figures 2 and 3 ) and CD34 + CD45 − events. 21 Experimental evidence suggests that CD34 +dim progenitors do have an efficient hematopoietic potential, 29 a finding which has been very recently acknowledged even by the ISHAGE group. In fact, whereas in the original guidelines 16 it was proposed to take into account CD34
+ events clearly identifiable in a cluster, in a more recent publication this indication was changed in that CD34 +dim events also were to be considered in the gating strategy. 24 Figure 4 , the two subsets of progenitors share the same morphological pattern. This finding supports the idea of considering even those progenitors which are CD45 − in the CD34 + cell calculation. As a general approach to the matter, we do not regard either CD45 or CD38 as good candidates to enumerate CD34 + events. Similar to CD45, even CD38 underestimates the true content of CD34 + cells as it stains у90% of CD34 + progenitors from G-CSF-mobilized peripheral blood, 35 such that a fraction accounting for 5-10% cannot be reliably identified with this marker. In fact, our single-staining protocol yielded the greatest number of CD34 + cells/kg and the ISHAGE one the lowest (Table 2 ). This figure is unlikely to result from an erroneous overestimation since it is consistent with the clinical data demonstrating a better correlation between time to ANC/PLT engraftment and the number of CD34 + cells/kg as calculated with our method (Table 2) . Finally, a significant correlation between each method and the number of CFU-GM was found, confirming the optimal collection of hematopoietic precursors. A further step in the analysis consisted of the assessment of the 'agreement' between the three methods. It represents an alternative comparison, based on graphical techniques and simple calculations, which takes its origin from the observation that tests of significance and correlation are not the correct statistical approaches as currently believed. 28 Figure 5 shows that the three methods under study are comparable and therefore interchangeable due to a very low degree of 'disagreement'. Since the three protocols produce a high agreement, choosing the most convenient in terms of costs, simplicity, time-saving and compliance with clinical results appears to be logical consequence. In this regard, the sequential gating strategy of the ISHAGE protocol requires more manual work as compared to Milan/Mulhouse and our protocol, and still involves a certain degree of subjectivity. As the gating procedure was identified as one of the major variables affecting the reproducibility of the methods for CD34+ cell enumeration, 36 the demand for simple, even though standardized, strategies is obvious. In conclusion, for clinical purposes the use of PE-conjugated 8G12 in a single staining assay appears reliable and feasible when rigorous procedures for sample preparation and acquisition are followed and an adequate software for multiparametric analysis is available. In our hands, this method has generated values of CD34 + cells highly consistent with clinical outcome. Although we are not in favor of implementing strenuous attempts to define complex gating strategies or to develop double/triple staining assay for CD34
+ cell quantitation, we certainly agree with the need for standardized guidelines. Therefore, we we hope that future efforts will specifically be devoted to address more relevant issues, such as (1) optimal sample preparation; (2) replacement of traditional dual-platform by a single-platform assay; (3) better definition of the phenotypic profile of CD34 + cells since experimental and clinical evidence suggests that some subsets of progenitors have long-term repopulating capacity, 37 whereas others, for instance those expressing adhesion molecules, [38] [39] [40] show a significant correlation with a short-term engraftment. This will be of great clinical interest owing to the availability of advanced technology such as high speed sorting able to isolate subsets of CD34 + progenitors.
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